These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25992447)

  • 1. RNA interference-based therapeutics: molecular platforms for infectious diseases.
    Dyawanapelly S; Ghodke SB; Vishwanathan R; Dandekar P; Jain R
    J Biomed Nanotechnol; 2014 Sep; 10(9):1998-2037. PubMed ID: 25992447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for the potential of RNA interference in the treatment of autoimmune diseases: Small interfering RNAs in the spotlight.
    Gorabi AM; Kiaie N; Aslani S; Jamialahmadi T; Johnston TP; Sahebkar A
    J Autoimmun; 2020 Nov; 114():102529. PubMed ID: 32782117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses.
    DeVincenzo JP
    Antivir Ther; 2012; 17(1 Pt B):213-25. PubMed ID: 22311654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics.
    Akhtari J; Tafazoli A; Mehrad-Majd H; Mahrooz A
    Curr Clin Pharmacol; 2018; 13(3):173-182. PubMed ID: 29992895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current issues of RNAi therapeutics delivery and development.
    Haussecker D
    J Control Release; 2014 Dec; 195():49-54. PubMed ID: 25111131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
    Takahashi Y; Nishikawa M; Takakura Y
    Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA interference-based therapy and its delivery systems.
    Chen X; Mangala LS; Rodriguez-Aguayo C; Kong X; Lopez-Berestein G; Sood AK
    Cancer Metastasis Rev; 2018 Mar; 37(1):107-124. PubMed ID: 29243000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference silencing the transcriptional message: aspects and applications.
    Karkare S; Daniel S; Bhatnagar D
    Appl Biochem Biotechnol; 2004 Oct; 119(1):1-12. PubMed ID: 15496724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers.
    Karim ME; Tha KK; Othman I; Borhan Uddin M; Chowdhury EH
    Pharmaceutics; 2018 May; 10(2):. PubMed ID: 29861465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in RNAi-based antiviral therapeutics.
    Zhou J; Rossi JJ
    Methods Mol Biol; 2011; 721():67-75. PubMed ID: 21431679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.
    Deng Y; Wang CC; Choy KW; Du Q; Chen J; Wang Q; Li L; Chung TK; Tang T
    Gene; 2014 Apr; 538(2):217-27. PubMed ID: 24406620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA interference: the molecular immune system.
    Bagasra O; Prilliman KR
    J Mol Histol; 2004 Aug; 35(6):545-53. PubMed ID: 15614608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference and its current application in mammals.
    Shen WG
    Chin Med J (Engl); 2004 Jul; 117(7):1084-91. PubMed ID: 15265387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring RNAi as a therapeutic strategy for controlling disease in aquaculture.
    Lima PC; Harris JO; Cook M
    Fish Shellfish Immunol; 2013 Mar; 34(3):729-43. PubMed ID: 23276883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current progress of siRNA/shRNA therapeutics in clinical trials.
    Burnett JC; Rossi JJ; Tiemann K
    Biotechnol J; 2011 Sep; 6(9):1130-46. PubMed ID: 21744502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State-of-the-art modified RNAi compounds for therapeutics.
    Carstea ED; Hough S; Wiederholt K; Welch PJ
    IDrugs; 2005 Aug; 8(8):642-7. PubMed ID: 16044372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases.
    Germain ND; Chung WK; Sarmiere PD
    Mol Aspects Med; 2023 Jun; 91():101148. PubMed ID: 36257857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of hairpin-based RNAi vectors for biological and therapeutic application.
    Boudreau RL; Davidson BL
    Methods Enzymol; 2012; 507():275-96. PubMed ID: 22365779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi and gene therapy: a mutual attraction.
    Grimm D; Kay MA
    Hematology Am Soc Hematol Educ Program; 2007; ():473-81. PubMed ID: 18024667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.